In DepthBiomedicine

Drug pair shows promise for treating sleep apnea

See allHide authors and affiliations

Science  21 Sep 2018:
Vol. 361, Issue 6408, pp. 1174-1175
DOI: 10.1126/science.361.6408.1174

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Summary

For decades, scientists have searched in vain for drugs to defeat obstructive sleep apnea, the risky and increasingly prevalent condition in which a person's upper airway repeatedly collapses during sleep, causing them to briefly stop breathing dozens or hundreds of times each night. Now, a new drug combination has reawakened hopes of treating sleep apnea with medication instead of the cumbersome breathing machines that saddle sufferers with a mask and headgear at night. The pills, atomoxetine and oxybutynin, have long been approved by the Food and Drug Administration for treating unrelated conditions. But when a team led by researchers at Brigham and Women's Hospital in Boston gave them before bedtime to 20 patients, their number of hourly airway obstructions fell dramatically, from a median of 28.5 to a median of 7.5. "That's actually unbelievably exciting," says Sigrid Veasey, a physician-researcher who studies sleep at the University of Pennsylvania who was not involved with the study.